Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma
Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma Ming-Huang Chen1., Wu-Lung R. Yang2., Kuan-Ting Lin3,4., Chia-Hung Liu4,5., Yu-Wen Liu1., Kai-Wen Huang6., Peter Mu-Hsin Chang1, Jin-Mei Lai7, Chun-Nan Hsu4,8, Kun-Mao Chao2,5, Cheng-Yan Kao2,5, Chi-Ying F. Huang1,3,9* 1 Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, 2 Department of Computer Science and Information Engineering, National Taiwan University, Taipei, Taiwan, 3 Institute of Biomedical Informatics, National Yang-Ming University, Taipei, Taiwan, 4 Institute of Information Science, Academia Sinica, Taipei, Taiwan, 5 Graduate Institute of Biomedical Electronic and Bioinformatics, National Taiwan University, Taipei, Taiwan, 6 Department of Surgery & Hepatitis Research Center, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan, 7 Department of Life Science, Fu-Jen Catholic University, New Taipei City, Taiwan, 8 Information Sciences Institute, University of Southern California, Marina del Rey, California, United States of America, 9 Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan Abstract Hepatocellular carcinoma (HCC) is an aggressive tumor with a poor prognosis. Currently, only sorafenib is approved by the FDA for advanced HCC treatment; therefore, there is an urgent need to discover candidate therapeutic drugs for HCC. We hypothesized that if a drug signature could reverse, at least in part, the gene expression signature of HCC, it might have the potential to inhibit HCC-related pathways and thereby treat HCC. To test this hypothesis, we first built an integrative platform, the ‘‘Encyclopedia of Hepatocellular Carcinoma genes Online 2’’, dubbed EHCO2, to systematically collect, organize and compare the publicly available data from HCC studies.
[Show full text]